摘要
目的系统评价生脉散治疗糖尿病合并冠状动脉粥样硬化性心脏病的临床效果。方法通过检索CNKI、WanFang、VIP、CBM、PubMed、Springer、NoteExpress以及The Cochrane Library,收集生脉散治疗糖尿病合并冠状动脉粥样硬化性心脏病的随机对照试验(RCT),检索时间自建库至2021年2月。由两人根据文献纳入与排除标准以及结局指标对所有文献进行筛选,采用Rev Man 5.3软件进行Meta分析。结果共纳入16个RCT,1224例患者,对照组611例,观察组613例。显示使用生脉散治疗糖尿病合并冠状动脉粥样硬化性心脏病对于提高临床有效率[RR=1.29,95%CI(1.21,1.37),Z=8.36,P<0.00001],改善空腹血糖[MD=-2.65,95%CI(-3.16,-2.13),Z=10.03,P<0.00001]、餐后2 h血糖[MD=-2.59,95%CI(-3.23,-1.95),Z=7.94,P<0.00001]、动态心电图缺血性ST-T水平[MD=-5.06,95%CI(-6.96,-3.15),Z=5.19,P<0.00001]、同型半胱氨酸水平[SMD=-0.44,95%CI(-0.64,-0.24),Z=4.34,P<0.0001]、C反应蛋白水平[MD=-1.53,95%CI(-1.90,-1.16),Z=8.14,P<0.00001]等方面观察组均优于对照组。结论生脉散联合常规治疗可以提升糖尿病合并冠状动脉粥样硬化性心脏病的临床疗效,但由于本研究的局限性,降低了研究结果的可靠性,还需更多高质量研究进一步提升结果的可靠性。
Objective To systematically evaluate the clinical effect of Shengmai San(生脉散)in the treatment of diabetes mellitus complicated with coronary heart disease.Methods All of randomized controlled trials(RCT)about the Shengmai San in treatment of diabetes mellitus complicated with coronary heart disease were retrieved in CNKI,Wan Fang,VIP,CBM,PubMed,Springer,Note Express and The Cochrane Library from database inception to February 2021.Two researcher screened all the literature based on the literature inclusion and exclusion criteria and outcome indicators,and used RevMan5.3 software for meta-analysis.Results A total of 16 RCTs,1224 patients,611 cases in the control group,and 613 cases in the observation group were included.The results show that the use of Shengmai San for the treatment of diabetes with coronary heart disease can improve the clinical effective rate[RR=1.29,95%CI(1.21,1.37),Z=8.36,P<0.00001],and improve fasting blood glucose[MD=-2.65,95%CI(-3.16,-2.13),Z=10.03,P<0.00001],2h postprandial blood glucose[MD=-2.59,95%CI(-3.23,-1.95),Z=7.94,P<0.00001],Holter ischemic ST-T level[MD=-5.06,95%CI(-6.96,-3.15),Z=5.19,P<0.00001],homocysteine level[SMD=-0.44,95%CI(-0.64,-0.24),Z=4.34,P<0.0001],C-reactive protein level[MD=-1.53,95%CI(-1.90,-1.16),Z=8.14,P<0.00001]The observation group is better than the control group in other aspects.Conclusion Shengmai San combined with conventional treatment can improve the clinical efficacy of diabetes complicated with coronary heart disease,but due to the limitations of this study,the reliability of the results is reduced,and more high-quality studies are needed to further improve the reliability of the results.
作者
甘德成
杨丽霞
米登海
李迈
GAN Decheng;YANG Lixia;MI Denghai;LI Mai(Gansu Provincial Hospital of Traditional Chinese Medicine,Lanzhou 730050,Gansu,China;Gansu Province Academy of Traditional Chinese Medicine,Lanzhou 730050,Gansu,China;Gansu University of Traditional Chinese Medicine,Lanzhou 730030,Gansu,China)
出处
《实用中医内科杂志》
2023年第2期39-42,153-155,共7页
Journal of Practical Traditional Chinese Internal Medicine
基金
甘肃省属科研院所条件建设专项(20JR10RA432)
陇药大品种二次开发及临床疗效评价行业技术中心项目(2019)
